Dabur Shares Drop 4% Amid US FDA Observations at Silvassa Plant

$DABUR ia shares declined over 4% on Monday despite the FMCG giant assuring investors that it is actively engaging with the US Food and Drug Administration (FDA) over observations made at its Silvassa manufacturing unit. In an exchange filing, Dabur stated that the FDA’s observations pertain only to a small section of the Silvassa facility in Dadra and Nagar Haveli. The company emphasised that the issues are limited in scope and it is working closely with the regulator to address them promptly. The development comes after an FDA inspection in January 2026 flagged concerns related to manufacturing practices and data integrity at the plant, which produces certain over-the-counter products. Market participants reacted cautiously, leading to the drop in the company’s stock price.